 Adrenergic beta-Antagonists
"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
| Descriptor ID |
D000319
|
| MeSH Number(s) |
D27.505.519.625.050.200.200 D27.505.696.577.050.200.200
|
| Concept/Terms |
Adrenergic beta-Antagonists- Adrenergic beta-Antagonists
- Adrenergic beta Antagonists
- beta-Antagonists, Adrenergic
- beta-Adrenergic Receptor Blockaders
- Blockaders, beta-Adrenergic Receptor
- Receptor Blockaders, beta-Adrenergic
- beta Adrenergic Receptor Blockaders
- beta-Adrenergic Blockers
- Blockers, beta-Adrenergic
- beta Adrenergic Blockers
- beta-Blockers, Adrenergic
- Adrenergic beta-Blockers
- beta Blockers, Adrenergic
- Adrenergic beta-Receptor Blockaders
- Adrenergic beta Receptor Blockaders
- Blockaders, Adrenergic beta-Receptor
- beta-Receptor Blockaders, Adrenergic
- beta-Adrenergic Blocking Agents
- Agents, beta-Adrenergic Blocking
- Blocking Agents, beta-Adrenergic
- beta Adrenergic Blocking Agents
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 3 | 2 | 5 | | 1993 | 2 | 0 | 2 | | 1994 | 3 | 0 | 3 | | 1996 | 7 | 3 | 10 | | 1997 | 3 | 0 | 3 | | 1998 | 5 | 2 | 7 | | 1999 | 4 | 1 | 5 | | 2000 | 4 | 0 | 4 | | 2001 | 7 | 4 | 11 | | 2003 | 5 | 3 | 8 | | 2004 | 3 | 2 | 5 | | 2005 | 2 | 4 | 6 | | 2006 | 3 | 2 | 5 | | 2007 | 4 | 1 | 5 | | 2008 | 7 | 1 | 8 | | 2009 | 3 | 0 | 3 | | 2010 | 5 | 2 | 7 | | 2011 | 4 | 4 | 8 | | 2012 | 8 | 2 | 10 | | 2013 | 8 | 1 | 9 | | 2014 | 4 | 3 | 7 | | 2015 | 3 | 2 | 5 | | 2016 | 4 | 0 | 4 | | 2017 | 4 | 4 | 8 | | 2018 | 1 | 3 | 4 | | 2019 | 3 | 5 | 8 | | 2020 | 0 | 2 | 2 | | 2021 | 0 | 2 | 2 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.
-
Huck DM, Rosenberg MA, Stauffer BL. Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers. J Hypertens. 2022 05 01; 40(5):1019-1029.
-
Vaduganathan M, Greene SJ, Zhang S, Solomon N, Chiswell K, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Mcdermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. J Card Fail. 2022 04; 28(4):554-563.
-
Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, Aleong R, Krueger SK, Sauer WH, Wilton SB, Rienstra M, van Veldhuisen DJ, Anand IS, White M, Camm AJ, Ziegler PD, Marshall D, Bristow MR, Connolly SJ. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 08; 14(8):e009591.
-
McDermott MT. Hyperthyroidism. Ann Intern Med. 2020 04 07; 172(7):ITC49-ITC64.
-
Samsky MD, Lin L, Greene SJ, Lippmann SJ, Peterson PN, Heidenreich PA, Laskey WK, Yancy CW, Greiner MA, Hardy NC, Kavati A, Park S, Mentz RJ, Fonarow GC, O'Brien EC. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. JAMA Cardiol. 2020 03 01; 5(3):292-299.
-
Biswas M, Levy A, Weber R, Tarakji K, Chung M, Noseworthy PA, Newton-Cheh C, Rosenberg MA. Multicenter Analysis of Dosing Protocols for Sotalol Initiation. J Cardiovasc Pharmacol Ther. 2020 05; 25(3):212-218.
-
Xie JX, Gunzburger EC, Kaun L, Plomondon ME, Barón AE, Waldo SW, Virani SS, Maddox TM, Mavromatis K. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
-
Cuneo BF, Kaizer AM, Clur SA, Swan H, Herberg U, Winbo A, Rydberg A, Haugaa K, Etheridge S, Ackerman MJ, Dagradi F, Killen SAS, Wacker-Gussmann A, Benson DW, Wilde AAM, Pan Z, Lam A, Spazzolini C, Horigome H, Schwartz PJ. Mothers with long QT syndrome are at increased risk for fetal death: findings from a multicenter international study. Am J Obstet Gynecol. 2020 03; 222(3):263.e1-263.e11.
-
Page RL, Allen LA. Cocaine, Heart Failure, and Carvedilol: Triangulating the Safety of ß-Blocker Therapy. JACC Heart Fail. 2019 09; 7(9):779-781.
-
Cardet JC, Jiang X, Lu Q, Gerard N, McIntire K, Boushey HA, Castro M, Chinchilli VM, Codispoti CD, Dyer AM, Holguin F, Kraft M, Lazarus S, Lemanske RF, Lugogo N, Mauger D, Moore WC, Moy J, Ortega VE, Peters SP, Smith LJ, Solway J, Sorkness CA, Sumino K, Wechsler ME, Wenzel S, Israel E. Reply. J Allergy Clin Immunol. 2019 09; 144(3):873-874.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|